What Investors Want to Know: How 32 Biosciences is Transforming Microbiome Medicine

 At 32 Biosciences, we are solving the problem of understanding and managing the gut microbiome, which is linked to a wide range of chronic diseases. Despite its vital role, the gut microbiome is largely overlooked in clinical practice because there is no quantitative definition of its health. We are addressing this gap by developing platform technologies: a diagnostic management tool to measure the functional health of the gut microbiome and microbiome-based interventions to restore balance, prevent, and treat disease.

The inspiration came from groundbreaking research by our scientific founders at The University of Chicago and the University of Wisconsin-Madison, coupled with the clear unmet need in healthcare. The gut microbiome is an untapped frontier in medicine, with the potential to revolutionize how we approach chronic disease. When I saw the convergence of pioneering science and a massive opportunity to make a meaningful impact on people’s health, I knew I had to take the leap.

The microbiome space is growing, but most players are focused on general probiotics or prebiotics, without clinical validation. What differentiates 32 Biosciences is our foundation in science. Our diagnostic management tool quantitatively defines the functional health of the gut microbiome—something no other technology offers. Additionally, our microbiome-based interventions are backed by cutting-edge research and designed to address specific medical needs, such as preventing surgical site infections. Our team of world-leading scientific founders and experienced business leaders also gives us a unique competitive edge.

My biggest pride is building a company that bridges groundbreaking science with real-world applications that can transform healthcare. Seeing the dedication of our team, the traction we’ve gained with investors, and the enthusiasm from potential partners validates the hard work we’ve put into 32 Biosciences. I’m particularly proud of our ability to secure significant non-dilutive funding to advance our R&D while preserving investor capital for commercialization.

In 12 months, we plan to complete R&D and secure FDA clearance for our GB-0001 diagnostic management tool. For our CS-0003 microbiome-based intervention, we aim to file an IND and initiate Phase 1 clinical trials. On the financial side, we will have launched and closed our Series A funding round, allowing us to scale development and commercial planning. These milestones will position us to advance our mission of improving healthspan and longevity.

Success for 32 Biosciences means transforming healthcare by making the gut microbiome a central focus of medical practice. It’s about delivering innovative, clinically validated tools and interventions that empower patients and clinicians to improve health outcomes. On a broader level, it’s building a company that not only drives significant investor returns but also sets the standard in microbiome medicine, ultimately creating a lasting impact on global health.